Company profile for Orasis Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ORASIS IS DEVELOPING a corrective eye drop to treat presbyopia as an alternative to reading glasses. Presbyopia, the inability to focus on near objects, typically occurs after the age of 40 and affects more than 1.8 billion people worldwide. Our product is an eye drop being developed to improve the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-stu...
ORASIS IS DEVELOPING a corrective eye drop to treat presbyopia as an alternative to reading glasses. Presbyopia, the inability to focus on near objects, typically occurs after the age of 40 and affects more than 1.8 billion people worldwide. Our product is an eye drop being developed to improve the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, our winning combination targets the right balance of efficacy, safety and comfort.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
6 Maskit St., Herzliya P.O.B 12929, 4673328 Israel
Telephone
Telephone
+972-9-8877745
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-expands-access-to-qlosi-with-new-starter-packs-for-eye-care-professionals-bolstering-commerical-rollout-302613523.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-announces-licensing-agreement-with-optus-pharmaceuticals-for-commercialization-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-in-korea-302277027.html

PR NEWSWIRE
16 Oct 2024

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-strengthens-leadership-team-with-key-hires-to-support-the-launch-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-302274366.html

PR NEWSWIRE
14 Oct 2024

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-completes-78-million-financing-to-support-commercial-launch-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-302269236.html

PR NEWSWIRE
08 Oct 2024

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-for-the-treatment-of-presbyopia-301959581.html

PR NEWSWIRE
19 Oct 2023

https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-announces-phase-2b-trial-efficacy-and-safety-results-of-novel-presbyopia-eye-drop-candidate-csf-1-at-the-2022-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting-301530823.html

PRNEWSWIRE
25 Apr 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty